Screening for Autoimmune Markers Is Unnecessary during Follow-up of Adults with Autoimmune Thrombocytopenic Purpura and no Autoimmune Markers at Onset

 

 Buy Article Permissions and Reprints

Summary

In an attempt to evaluate the frequency of autoimmune markers in autoimmune thrombocytopenic purpura (AITP) and to determine if autoimmune markers in patients with isolated AITP were associated with particular disease manifestations, we analyzed records of 122 consecutive adults with AITP. Twenty-nine patients (24%) had significant titers of one or several autoimmune markers at AITP onset. Among them, 16 (13%) had antinuclear antibodies. The presence of autoimmune markers did not correlate with presenting feature, response to treatment or long-term outcome of AITP. Six patients (5%) developed seven autoimmune diseases during follow-up, comprising systemic lupus erythematosus, an antiphospholipid syndrome, autoimmune haemolytic anemia (n = 2), Grave’s disease, Hashimoto’s disease and primary biliary cirrhosis. At AITP onset, three of these patients had isolated biological markers of the autoimmune disease they later developed. The annual average incidence rate of autoimmune diseases was 1% per patient-year in the entire group and 0.4% in the group of patients with no autoimmune markers at AITP onset. This low rate is probably due to careful assessment at diagnosis for concomitant overt autoimmune disease. We recommend extensive screening for autoimmune markers at AITP onset, and careful follow-up of patients with autoimmune markers. Routine screening for autoimmune markers during AITP follow-up is not necessary for patients with no autoimmune markers at AITP onset.

Systemic lupus erythematosus (SLE) and other autoimmune disorders can complicate autoimmune thrombocytopenic purpura (AITP) or be diagnosed concomitantly with otherwise unremarkable AITP (1, 2). However, the frequency and prognostic value of isolated autoimmune markers (i. e. not associated with an autoimmune disorder), particularly antinuclear antibodies (ANA) at AITP onset or during follow-up is controversial (3-8). For example, the committee organized by George et al. (9) to write guideline on the diagnosis and treatment of AITP stated that the search for ANA and lupus anticoagulant were of “uncertain appropriateness at diagnosis and during follow-up”. In an attempt to help practicians to make decisions, we analyzed the frequency of autoimmune markers and autoimmune disorders at onset and during the follow-up in 122 adults with AITP and no overt autoimmune disease at diagnosis. These consecutive patients were followed by the same physician for a mean period of 6 years, and had routine screening tests for autoimmune markers and disorders at onset, before steroid therapy, and regularly during follow-up.

• References

• 1 Boumpas DT, Austin HA, Fessler BJ, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concept Part I: renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 1995; 122: 940-50.
  CrossrefPubMedGoogle Scholar
• 2 Mestanza-Peralta M, Ariza-Ariza R, Cardiel MH, Alcocer-Varela J. Thrombocytopenic purpura as initial manifestation of systemic lupus erythematosus. J Rheumatol 1997; 24: 867-70.
  PubMedGoogle Scholar
• 3 Morley KD, Bernstein RM, Bunn CC, Gharavi AE, Fortin MT, Chipping PM, Hughes GRV. Thrombocytopenia and anti-Ro. Lancet 1981; ii: 940.
  PubMedGoogle Scholar
• 4 Anderson MJ, Peebles CL, McMillan R, Curd JG. Fluorescent antinuclear antibodies and anti-SS-A/Ro in patients with immune thrombocytopenia subsequently developing systemic lupus erythematosus. Ann Intern Med 1985; 103: 548-51.
  CrossrefPubMedGoogle Scholar
• 5 Perez HD, Katler E, Embury S. Idiopathic thrombocytopenic purpura with high-titer, speckled pattern antinuclear antibodies: possible marker for systemic lupus erythematosus. Arthritis Rheum 1985; 28: 596-7.
  CrossrefPubMedGoogle Scholar
• 6 Panzer S, Penner E, Graninger W, Schulz E, Smolen JS. Antinuclear antibodies in patients with chronic idiopathic autoimmune thrombocytopenia followed 2-30 years. Am J Hematol 1989; 32: 100-3.
  CrossrefPubMedGoogle Scholar
• 7 Kurata Y, Miyagawa S, Kosugi S. et al. High-titer antinuclear antibodies, anti-SS-A/Ro antibodies and antinuclear RNP antibodies in patients with idiopathic thrombocytopenic purpura. Thromb Haemost 1994; 71: 184-7.
  PubMedGoogle Scholar
• 8 George JN, El-Harake MA, Easkob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1994; 331: 1207-11.
  CrossrefPubMedGoogle Scholar
• 9 George JN, Woolf SH, Raskob GE. et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 2-40.
  PubMedGoogle Scholar
• 10 Tan E, Cohen AS, Fries JF. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
  CrossrefPubMedGoogle Scholar
• 11 Piette JC. Diagnosis and classification criteria for the antiphospholipid/ cofactors syndrome: a “mission impossible”?. Lupus 1996; 05: 354-63.
  CrossrefPubMedGoogle Scholar
• 12 Picozzi VJ, Roeske WR, Creger WP. Fate of therapy failures in adult idiopathic thrombocytopenic purpura. Am J Med 1980; 69: 690-4.
  CrossrefPubMedGoogle Scholar
• 13 Vantelon JM, Godeau B, Bierling P. Modalités évolutives et réponses aux traitements du purpura thrombopénique auto-immun de l’adulte: à propos d’une série monocentrique de 122 cas. Rev Med Interne 1997; 18 (Suppl. 02) 114.
  CrossrefPubMedGoogle Scholar
• 14 Bompas DT, Barez S, Klippel J, Balow JE. Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 1990; 112: 674-7.
  CrossrefPubMedGoogle Scholar
• 15 Stasi R, Stipa E, Masi M. et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98: 436-42.
  CrossrefPubMedGoogle Scholar
• 16 Finazzi G, Brancaccio V, Moia M. et al. Natural history and risk factor for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from Italian registry. Am J Med 1996; 100: 530-6.
  CrossrefPubMedGoogle Scholar